MX2022012885A - Composicion liposomal para la prevencion o tratamiento precoz de una infeccion patogena. - Google Patents

Composicion liposomal para la prevencion o tratamiento precoz de una infeccion patogena.

Info

Publication number
MX2022012885A
MX2022012885A MX2022012885A MX2022012885A MX2022012885A MX 2022012885 A MX2022012885 A MX 2022012885A MX 2022012885 A MX2022012885 A MX 2022012885A MX 2022012885 A MX2022012885 A MX 2022012885A MX 2022012885 A MX2022012885 A MX 2022012885A
Authority
MX
Mexico
Prior art keywords
liposomal composition
early treatment
pathogenic infection
preventing
prevention
Prior art date
Application number
MX2022012885A
Other languages
English (en)
Inventor
Jes Dietrich
Peter Andersen
Frank Follmann
Dennis Christensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MX2022012885A publication Critical patent/MX2022012885A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición liposomal para el uso como un medicamento. En particular, la presente invención se refiere a una composición liposomal para el uso en la prevención o el tratamiento precoz de una infección patógena. Más específicamente, la composición liposomal se usa para la prevención, o el tratamiento precoz, de una infección patógena en el tracto respiratorio, preferiblemente por medio de la administración nasal o pulmonar.
MX2022012885A 2020-04-15 2021-04-15 Composicion liposomal para la prevencion o tratamiento precoz de una infeccion patogena. MX2022012885A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20169618 2020-04-15
EP20201268 2020-10-12
PCT/EP2021/059807 WO2021209562A1 (en) 2020-04-15 2021-04-15 Liposomal composition for preventing or early treatment of pathogenic infection

Publications (1)

Publication Number Publication Date
MX2022012885A true MX2022012885A (es) 2023-01-16

Family

ID=75438810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012885A MX2022012885A (es) 2020-04-15 2021-04-15 Composicion liposomal para la prevencion o tratamiento precoz de una infeccion patogena.

Country Status (9)

Country Link
US (1) US20230225972A1 (es)
EP (1) EP4135653A1 (es)
JP (1) JP2023521827A (es)
KR (1) KR20230002680A (es)
CN (1) CN115515561A (es)
AU (1) AU2021257050A1 (es)
BR (1) BR112022020597A2 (es)
MX (1) MX2022012885A (es)
WO (1) WO2021209562A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
AU2008271756B2 (en) * 2007-06-29 2012-10-04 Statens Serum Institut The use of monomycolyl glycerol (MMG) as an adjuvant
CN103619325A (zh) * 2011-07-04 2014-03-05 国立血清研究所 用于生产脂质体的方法
JP6257607B2 (ja) * 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド 癌免疫療法のための組成物および方法
WO2017220099A1 (en) * 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties

Also Published As

Publication number Publication date
EP4135653A1 (en) 2023-02-22
BR112022020597A2 (pt) 2022-11-29
AU2021257050A1 (en) 2022-10-27
US20230225972A1 (en) 2023-07-20
KR20230002680A (ko) 2023-01-05
JP2023521827A (ja) 2023-05-25
WO2021209562A1 (en) 2021-10-21
CN115515561A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
MX2021013679A (es) Compuestos antivirales que contienen nitrilo.
PH12020551762A1 (en) Peptide macrocycles against acinetobacter baumannii
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
MX2021013934A (es) Compuestos y metodos para el tratamiento de covid-19.
HK1156847A1 (en) Pharmaceutical formulations and methods for treating respiratory tract infections
EA201100305A1 (ru) Лечение респираторных заболеваний
WO2010111650A3 (en) Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EA201590835A1 (ru) Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
MY174002A (en) Combination theraphy for the treatment of diabetes
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EA201590933A1 (ru) Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2022012135A (es) Métodos para tratar la enfermedad de coronavirus de 2019.
MX2022012885A (es) Composicion liposomal para la prevencion o tratamiento precoz de una infeccion patogena.
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
WO2014193269A3 (ru) Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций
MX2022013722A (es) Cisteamina para el tratamiento de infección por sars-cov-2.
WO2022023533A3 (en) Antiviral use of liraglutide and gefitinib